SCHEMBL285984

SCHEMBL285984

CCCCc1noc(C)c1CCc1nc(C)c(C(=O)OC)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
HPGD P15428 5/20 0.38
TSHR P16473 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
RAB9A P51151 5/20 0.36
NPC1 O15118 4/20 0.36
KDM4E B2RXH2 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 5/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
GLA P06280 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285957 0.87 ALDH1A1 (0.38) HPGDTSHRL3MBTL1RAB9ANPC1
SCHEMBL285588 0.86 KMT2A (0.41) POLBTSHRL3MBTL1ALDH1A1HTT
SCHEMBL286082 0.86 KMT2A (0.41) POLBTSHRL3MBTL1ALDH1A1HTT
SCHEMBL286243 0.86 KMT2A (0.41) POLBTSHRL3MBTL1ALDH1A1HTT
SCHEMBL286186 0.86 L3MBTL1 (0.37) POLBL3MBTL1KDM4EALDH1A1LMNA
SCHEMBL286187 0.85 POLB (0.38) POLBHPGDTSHRL3MBTL1RAB9A
SCHEMBL285936 0.85 L3MBTL1 (0.32) POLBTSHRL3MBTL1ALDH1A1GLA
SCHEMBL285935 0.82 L3MBTL1 (0.35) L3MBTL1ALDH1A1TP53GAA
SCHEMBL286026 0.82 POLB (0.41) POLBHPGDTSHRNPSR1L3MBTL1
SCHEMBL286081 0.81 ZAP70 (0.35) L3MBTL1ALDH1A1TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-B1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN LA ROCHE (CH) 2016-09-28 EP disclosed
US-8178522-B2 Thiazoles HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127974-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286116-A1 THIAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286116-A1 THIAZOLES GABRA5, GABRA1, GABRA4 POLB 4094/4885HPGD 1522/4885TSHR 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.